



Alain Combes
Marco Ranieri

Rescue therapy for refractory ARDS should be offered early: yes

Received: 13 February 2015
Accepted: 25 February 2015
Published online: 20 March 2015
© Springer-Verlag Berlin Heidelberg and ESICM 2015

For contrasting viewpoints, please go to
doi:[10.1007/s00134-015-3704-6](https://doi.org/10.1007/s00134-015-3704-6) and doi:[10.1007/s00134-015-3708-2](https://doi.org/10.1007/s00134-015-3708-2).

A. Combes (✉)

Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, iCAN, Institute of Cardiometabolism and Nutrition, 47 Boulevard de L'Hôpital, 75651 Paris Cedex 13, France
e-mail: alain.combes@psl.aphp.fr

M. Ranieri

Università “La Sapienza” di Roma, Policlinico Umberto I, Anesthesia and Critical Care Medicine, Rome, Italy
e-mail: mraniieri@unito.it

Clinical vignette A previously healthy 51-year-old woman (height 165 cm, weight 60 kg) was admitted to the ICU with severe community acquired pneumonia. She required intubation and mechanical ventilation 6 h after admission. Her respiratory status declined continuously over the next few hours. Twelve hours after admission, blood gases were as follows: pH = 7.36, PaCO₂ = 47 mmHg, PaO₂ = 65 mmHg, HCO₃⁻ = 26 mmol/L on FiO₂ = 100 %, Vt set at 340 ml, PEEP at 8 cmH₂O, respiratory rate at 28/min, and plateau pressure measured at 28 cmH₂O. She was hemodynamically stable and had a normal renal function.

This patient has severe ARDS according to the Berlin definition [1]. This patient has very low respiratory system compliance (18 ml/cmH₂O) and is ventilated with a high driving pressure (20 cmH₂O). Hypoxemia is

extremely severe with a high oxygenation index (43 cmH₂O/mmHg). Recent clinical studies showed that hospital mortality in patients experiencing such severe forms of ARDS ranges from 45 to 60 % [1–6].

What are the first-line options in this situation?

This patient receives only 8 cmH₂O of PEEP. While higher PEEP confers a survival advantage in severe ARDS patients [7], higher levels of PEEP in this patient very likely will further increase the plateau pressure to levels that are certainly associated with an increased risk of ventilator-induced lung injury. Inhaled nitric oxide might have improved arterial oxygenation although this intervention was not shown to improve long-term survival. On the other hand, prone positioning should be rapidly initiated for more than 16 h since a significant increase in survival [8] has been observed in patients with severe ARDS with this maneuver. This patient should also receive continuous infusion of neuromuscular blockade agents [9].

What is the rationale for applying “ultraprotective” MV in this situation?

Lung hyperinflation occurs in approximately 30 % of ARDS patients ventilated using the protective ARDSNet strategy [10]. Moreover, Hager and co-workers retrospectively analyzing data of the “ARDSNet” trial group show a linear relationship between mortality and P_{plat}—a linear relationship in the sense that the lower P_{plat}, the lower the mortality, even for P_{plat} less than 30 cmH₂O [11]. In a proof of concept study, Terragni et al. [12] demonstrated that very low tidal volume ventilation

(3.5–5 ml/kg) and lower P_{plat} (less than 25 cmH₂O) enhance lung protection as indicated by the significant attenuation of the pro-inflammatory signal observed at the pulmonary level.

Because V_t reduction to below 6 ml/kg to achieve P_{plat} less than 25 cmH₂O may induce severe hypercapnia, this “ultraprotective” MV strategy may not be possible without the recourse to extracorporeal carbon dioxide removal (ECCO₂-R) which only provides CO₂ removal or venovenous extracorporeal membrane oxygenation (ECMO) which achieves complete extracorporeal blood oxygenation and CO₂ removal.

Why should ECMO be initiated rapidly in this patient?

The patient’s lung mechanics and blood gases should be carefully monitored during the prone positioning trial and after turning the patient back to the supine position. In the situation of major improvement of lung compliance and blood oxygenation following this trial, conventional MV should be continued until the patient can be safely extubated. Alternatively, if low respiratory system compliance and severe hypoxemia persist, venovenous ECMO should be instituted as soon as possible for the following reasons.

First, to achieve “ultraprotective” low volume and low pressure MV in this severely hypoxemic patient, ECMO should be preferred over ECCO₂-R. Under ECMO, V_t should be dramatically reduced to achieve P_{plat} less than 25 cmH₂O, with PEEP greater than 12 cmH₂O, since these settings were shown to be independently associated with better outcomes [4, 13].

Second, modern ECMO devices are simpler, safer, require less anticoagulation, and are associated with fewer bleeding complications and it is now possible to support patients for weeks [14].

Third, recent series and a randomized trial demonstrated better survival for patients receiving ECMO for severe ARDS [2–4, 15]. The CESAR trial [3] evaluated a strategy of transfer to a single center which had ECMO capability while the patients randomized to the control group received conventional MV. Mortality or severe disability 6 months after randomization was lower for the 90 patients randomized to the ECMO group (37 vs 53 %, $p = 0.03$). Interestingly, more than 60 % of the randomized patients suffered pneumonia and their mean $\text{PaO}_2/\text{FiO}_2$ (76 mmHg) was higher than that of the patient

described herein. A British collaborative cohort series of pandemic influenza A (H1N1)-induced ARDS patients also showed significantly lower mortality (24 vs 51 %) after propensity matching for 80 patients transferred to ECMO referral centers [2].

Fourth, factors strongly associated with poorer outcomes in series of severe ARDS patients receiving ECMO were older age, a greater number of days of MV before ECMO, a higher number of organ failures, low pre-ECMO respiratory system compliance, absence of paralysis or prone positioning before ECMO, and immunosuppression [15, 16]. Based on these factors, predictive survival models have been developed to help clinicians select appropriate candidates for ECMO. Interestingly, according to the recently developed RESP [15] and PRESERVE [16] scoring systems, hospital mortality after ECMO initiation would be less than 20 % for the patient described above, should ECMO support be initiated within 48 h of tracheal intubation.

Lastly, a high incidence of cognitive impairment and psychiatric symptoms was demonstrated in long-term survivors of acute lung injury in the Fluid and Catheter Treatment Trial [17]. In that study, lower PaO_2 [86 (70–98) vs 71 (67–80) mmHg, $p = 0.02$] was associated with cognitive and psychiatric impairment 12 months following randomization. It can therefore be hypothesized that ECMO might improve long-term quality-of-life and cognitive function by improving blood oxygenation in severely hypoxemic ARDS patients. Indeed, patients randomized to the ECMO arm of the CESAR trial [3] or the 67 long-term survivors of the French multicenter ECMO-treated ARDS cohort [16] exhibited comparable or better of health-related quality-of-life scores than those reported by patients with less severe ARDS treated with conventional management [18].

In conclusion, a strong pathophysiological rationale and data from recent studies of ECMO for severe ARDS argue for the early initiation of ECMO in the patient described above. This strategy might decrease mortality from 45–50 % to less than 20 %, with potentially less cognitive and psychiatric impairment and improved health-related quality-of-life in long-term survivors. The currently ongoing ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial (NCT01470703) [19], an international multicenter randomized controlled trial comparing conventional MV with prone positioning to ECMO in very severe ARDS patients ($\text{PaO}_2/\text{FiO}_2$ less than 80 mmHg), might confirm this hypothesis.

Conflicts of interest Dr. Combes is the primary investigator of the EOLIA trial, NCT01470703, a randomized trial of VV-ECMO supported in part by MAQUET. Dr. Combes has received honoraria for lectures from MAQUET. Prof. Ranieri consulted for Hemodec, ALung, Maquet. He also lectured for Novalung. He was the PI of a Maquet supported trial on ECCO2R in patients with COPD.

References

- Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin definition. *JAMA* 307:2526–2533
- Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, Sadique MZ, Sekhon JS, McAuley DF, Firmin RK, Harvey C, Cordingley JJ, Price S, Vuylsteke A, Jenkins DP, Noble DW, Bloomfield R, Walsh TS, Perkins GD, Menon D, Taylor BL, Rowan KM (2011) Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). *JAMA* 306:1659–1668
- Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D (2009) Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet* 374:1351–1363
- Pham T, Combes A, Roze H, Chevret S, Mercat A, Roch A, Mourvillier B, Ara-Somohano C, Bastien O, Zogheib E, Clavel M, Constan A, Marie Richard JC, Brun-Buisson C, Brochard L (2013) Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. *Am J Respir Crit Care Med* 187:276–285
- Young D, Lamb SE, Shah S, MacKenzie I, Tunnicliffe W, Lall R, Rowan K, Cuthbertson BH (2013) High-frequency oscillation for acute respiratory distress syndrome. *N Engl J Med* 368:806–813
- Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE (2008) Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:637–645
- Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS, Pullenayegum E, Zhou Q, Cook D, Brochard L, Richard JC, Lamontagne F, Bhatnagar N, Stewart TE, Guyatt G (2010) Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. *JAMA* 303:865–873
- Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L (2013) Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 368:2159–2168
- Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guerin C, Prat G, Morange S, Roch A (2010) Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 363:1107–1116
- Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O, Gandini G, Herrmann P, Mascia L, Quintel M, Slutsky AS, Gattinoni L, Ranieri VM (2007) Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 175:160–166
- Hager DN, Krishnan JA, Hayden DL, Brower RG (2005) Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med* 172:1241–1245
- Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano C, Quintel M, Gattinoni L, Ranieri VM (2009) Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. *Anesthesiology* 111:826–835
- Schmidt M, Stewart C, Bailey M, Nieszkowska A, Kelly J, Murphy L, Pilcher D, Cooper DJ, Scheinkestel C, Pellegrino V, Forrest P, Combes A, Hodgson C (2015) Mechanical ventilation management during extracorporeal membrane oxygenation for acute respiratory distress syndrome: a retrospective international multicenter study. *Crit Care Med* 43:654–664
- MacLaren G, Combes A, Bartlett RH (2012) Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. *Intensive Care Med* 38:210–220
- Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, Scheinkestel C, Cooper DJ, Brodie D, Pellegrino V, Combes A, Pilcher D (2014) Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The respiratory extracorporeal membrane oxygenation survival prediction (RESP) score. *Am J Respir Crit Care Med* 189:1374–1382
- Schmidt M, Zogheib E, Roze H, Repesse X, Lebreton G, Luyt CE, Trouillet JL, Brechot N, Nieszkowska A, Dupont H, Ouattara A, Leprince P, Chastre J, Combes A (2013) The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *Intensive Care Med* 39:1704–1713
- Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, Localio AR, Demissie E, Hopkins RO, Angus DC (2012) The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. *Am J Respir Crit Care Med* 185:1307–1315
- Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS (2003) One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 348:683–693
- ClinicalTrials.gov (2014) EOLIA trial. <http://www.clinicaltrials.gov/ct2/show/NCT01470703?term=eolia&rank=1>. Accessed 14 Sept 2014



Daniel Brodie
Claude Guérin

Rescue therapy for refractory ARDS should be offered early: no

Received: 25 January 2015

Accepted: 16 February 2015

Published online: 20 March 2015

© Springer-Verlag Berlin Heidelberg and ESICM 2015

For contrasting viewpoints, please go to doi:

[10.1007/s00134-015-3708-2](https://doi.org/10.1007/s00134-015-3708-2) and doi:[10.1007/s00134-015-3721-5](https://doi.org/10.1007/s00134-015-3721-5).

D. Brodie (✉)

Division of Pulmonary, Allergy and Critical Care Medicine,
New York-Presbyterian Hospital, Columbia University College of
Physicians and Surgeons, 622 W. 168th St, PH 8E 101,
New York, NY 10032, USA
e-mail: hdb5@columbia.edu
Tel.: +1-212-305-9817

C. Guérin

Service de Réanimation Médicale, Hôpital de la Croix-Rousse,
103 Grande Rue de la Croix-Rousse, 69004 Lyon, France

C. Guérin

Hospices Civils de Lyon and Université de Lyon and INSERM
UMR 955 Eq13, Lyon, France

Clinical vignette A previously healthy 51-year-old woman was admitted to the ICU with severe community acquired pneumonia. She required intubation and mechanical ventilation 6 h after admission. Her respiratory status declined continuously over the next few hours and her $\text{PaO}_2/\text{FIO}_2$ ratio was 65 with a PEEP of 8 cmH_2O at 12 h after admission (plateau pressure was 28 cmH_2O). She was hemodynamically stable and had normal renal function.

Despite the remarkable hypoxemia in this case of severe ARDS, there is no rush to ECMO for several reasons; each related to the fact that aspects of the patient's current ventilator and non-ventilator management should be optimized prior to consideration of ECMO.

First of all, a low-volume, low-pressure ventilation strategy should be undertaken according to the protocols of the **ExPress** [1] or **ARDSNet ARMA** [2] trials. We are not

given information about the selected tidal volume (VT). However, it should be based on predicted body weight (PBW). As the patient in this case is a woman, it should be mentioned that **clinicians tend** to use **actual** body weight instead of PBW for assigning VT and **therefore over-ventilate women** and people who are of **shorter** stature [3]. PEEP should be set initially according to the protocol used (**standard** or **high PEEP** strategy) [4, 5] and is almost certainly too low in this case. Titration of PEEP may benefit the patient. Bear in mind that after raising PEEP, **plateau pressure (Pplat) may increase** well above 30 cmH_2O . However, **should the lung be recruited by the increase in PEEP, Pplat would then decrease**. Furthermore, **the assessment of oxygenation response to PEEP also requires only a few minutes** [6]. Is there room for Pplat greater than 30 cmH_2O due to impairment of elastic properties of the chest wall? Grasso et al. [7] were able to avoid ECMO in seven severe influenza A(H1N1)-associated ARDS patients with high chest wall elastance that allowed the PEEP to be raised in order to reach a **transpulmonary pressure of 25 cmH_2O** . Such measurements require the insertion of an **esophageal balloon**. A more common way of setting PEEP is to use a PEEP/ FIO_2 table. Suppose FIO_2 is 0.80 in this case, PaO_2 would be 52 mmHg and hence PEEP should range from 14 to 22 cmH_2O depending on the PEEP/ FIO_2 table [4, 5]. Even though the current concept for setting PEEP is the prevention of the cyclical opening and closing of alveoli during tidal breaths, in a patient like this, the oxygenation response to PEEP is relevant. The post hoc analysis of the trials on PEEP observed that the **oxygenation response to PEEP was associated with better outcomes in ARDS patients** [8]. Chiumello et al. [9] found that the **PEEP/ FIO_2 table was the only way to set lower PEEP in patients with low potential of recruitment and higher PEEP in patients with high potential of recruitment**. In line with the above considerations, a recruitment maneuver should be considered in this patient [10] followed by a higher level of PEEP than prior to the procedure.




Fig. 1 Management algorithm for patients with ARDS

The second aspect of her care to optimize is sedation and neuromuscular blockade. Deep sedation should be provided to reduce oxygen consumption and improve ventilator synchrony and, once a level of deep sedation is reached, a

neuromuscular blocking agent should be promptly started, ideally using cisatracurium for 48 h. With this medication, the oxygenation improves, the rate of pneumothorax is reduced, and the survival is improved [11].

The third item to consider is the **fluid balance**. With her normal renal function and stable hemodynamics, this patient is a good candidate for receiving **early diuretics**. Although a large randomized controlled trial **failed** to show a **beneficial** effect on **mortality** [12], a conservative fluid strategy was associated with **improvement** in the **oxygenation index** and improvements in ventilator- and ICU-free days. A separate randomized placebo-controlled trial showed that furosemide plus albumin significantly **improved oxygenation in hypoproteinemic** (plasma protein **less than 6 g/dl**) ARDS patients [13]. Should this patient be hypoproteinemic, this strategy is quite simple to improve oxygenation, and could be considered.

The fourth opportunity for optimization is in the use of **prone** positioning. The completion of previous steps should only require a couple of hours and, if the patient is still sufficiently hypoxemic, prone position should be instituted given that there are no known contraindications. **Caution** should be applied in centers that do **not** have **extensive experience** with prone positioning. In patients with ARDS and severity criteria ($\text{PaO}_2/\text{FIO}_2$ less than 150 mmHg with PEEP of at least 5 cmH₂O and FIO_2 of at least 0.6) a significant improvement in survival was demonstrated as compared to the supine position in the PROSEVA trial [14]. This **benefit** was also observed in the lowest quartile of $\text{PaO}_2/\text{FIO}_2$ at the time of randomization, which ranged from 45 to 87 mmHg. The current case in question is in this range. Proning should be performed in a complete prone position and for a prolonged session (**16 consecutive hours or more as scheduled in PROSEVA**).

The fifth item to consider would be inhaled pulmonary vasodilators: **inhaled epoprostenol** or **inhaled nitric oxide**.

These medications can be used in severe hypoxemia to **improve oxygenation** by **dilating pulmonary vascular beds** in those areas of the lungs **where ventilation is preserved**, thereby **decreasing** the proportion of blood **shunted** through areas of poor ventilation. It can be started while the patient is still in the supine position but several studies found an **additive** effect of **prone** position and nitric oxide on oxygenation. That said, **these medications do not change overall outcomes** and, given that the degree of hypoxemia in this case is not immediately life-threatening, delaying the decision for ECMO in order to institute these medications may not be necessary.

Where in the course of treating this patient should we consider ECMO (Fig. 1)? In a patient without life-threatening hypoxemia, **we would allow at least 6 h to decide whether** or not **ECMO** should be undertaken. The following **criteria** for **initiating ECMO** in ARDS patients have been recently proposed [15]: **$\text{PaO}_2/\text{FIO}_2$ ratio less than 80 despite high PEEP (15–20 cmH₂O) for at least 6 h** in patients with potentially reversible respiratory failure, or **hypercapnia** with acidemia (**pH less than 7.15**) or **Pplat greater than 35–45 cmH₂O**, depending on the patient's body habitus. A similar strategy is being tested in a multicenter randomized controlled trial and final results are expected in the near future.

Conflicts of interest Dr. Brodie previously received research support and provided research consulting for Maquet Cardiovascular. He is on the medical advisory board of ALung Technologies and Kadence (Johnson & Johnson). All compensation for his consulting goes to Columbia University.

References

1. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L (2008) Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:646–655
2. ARDSnet (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 342:1301–1308
3. Fish E, Novack V, Banner-Goodspeed VM, Sarge T, Loring S, Talmor D (2014) The Esophageal Pressure-Guided Ventilation 2 (EPVent2) trial protocol: a multicentre, randomised clinical trial of mechanical ventilation guided by transpulmonary pressure. *BMJ open* 4:e006356
4. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT (2004) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 351:327–336
5. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE (2008) Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:637–645
6. Chiumello D, Coppola S, Froio S, Mietto C, Brazzi L, Carlesso E, Gattinoni L (2013) Time to reach a new steady state after changes of positive end expiratory pressure. *Intensive Care Med* 39:1377–1385
7. Grasso S, Terragni P, Birocco A, Urbino R, Del Sorbo L, Filippini C, Mascia L, Pesenti A, Zangrillo A, Gattinoni L, Ranieri VM (2012) ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure. *Intensive Care Med* 38:395–403
8. Goligher EC, Kavanagh BP, Rubenfeld GD, Adhikari NK, Pinto R, Fan E, Brochard LJ, Granton JT, Mercat A, Marie Richard JC, Chretien JM, Jones GL, Cook DJ, Stewart TE, Slutsky AS, Meade MO, Ferguson ND (2014) Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials. *Am J Respir Crit Care Med* 190:70–76

9. Chiumello D, Cressoni M, Carlesso E, Caspani ML, Marino A, Gallazzi E, Caironi P, Lazzarini M, Moerer O, Quintel M, Gattinoni L (2014) Bedside selection of positive end-expiratory pressure in mild, moderate, and severe acute respiratory distress syndrome. *Crit Care Med* 42:252–264
10. Roeseler J, Sottiaux T, Lemiale V, Lesny M (2013) Prise en charge de la mobilisation précoce en réanimation, chez l'adulte et l'enfant (électrostimulation incluse). *Réanimation* 22:207–218
11. Papazian L, Forel J, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal J, Perez D, Seghboyan J et al (2010) Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 363:1107–1116
12. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, de Boisblanc B, Connors AF Jr, Hite RD, Harabin AL (2006) Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 354:2564–2575
13. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR (2005) A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. *Crit Care Med* 33:1681–1687
14. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gannier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L, Group PS (2013) Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 368:2159–2168
15. Brodie D, Bacchetta M (2011) Extracorporeal membrane oxygenation for ARDS in adults. *N Engl J Med* 365:1905–1914



Antoine Roch
Laurent Papazian

Rescue therapy for refractory ARDS should be offered early: we are not sure

Received: 13 February 2015
Accepted: 17 February 2015
Published online: 20 March 2015
© Springer-Verlag Berlin Heidelberg and ESICM 2015

For contrasting viewpoints, please go to
doi:10.1007/s00134-015-3704-6 and
doi:10.1007/s00134-015-3721-5.

A. Roch
Assistance Publique-Hôpitaux de Marseille, Hôpital Nord,
Service d'Accueil des Urgence, Marseille, France

L. Papazian (✉)
Assistance Publique-Hôpitaux de Marseille, Hôpital Nord,
Réanimation des Détresses Respiratoires et Infections Sévères,
13015 Marseille, France
e-mail: laurent.papazian@ap-hm.fr
Tel.: +33 491 965 835

A. Roch · L. Papazian
Aix-Marseille Université, Faculté de Médecine, URMITE UMR
CNRS 7278, Marseille, France

Clinical vignette A previously healthy 51-year-old woman was admitted to the intensive care unit (ICU) with severe community-acquired pneumonia. She required intubation and mechanical ventilation 6 h after admission. Her respiratory status declined continuously over the next few hours, and her PaO₂/FiO₂ ratio was 65 with a positive end-expiratory pressure (PEEP) at 8–12 h after admission (plateau pressure was 28). She was hemodynamically stable and had normal renal function.

Extracorporeal membrane oxygenation (ECMO) is an old technique which is highly dependent on development of new technologies. The concomitant publication of the CESAR trial [1] and the occurrence of the H1N1

2009–2010 pandemic [2] raised numerous questions about the place of ECMO in the symptomatic treatment of acute respiratory distress syndrome (ARDS). Schematically, ECMO should reach two objectives: to maintain adequate gas exchange when there is dramatic hypoxemia and/or profound acidosis with high degree of hypercapnia, and to preserve the lung from potential volu-, baro-, and bio-trauma associated with mechanical ventilation. We should therefore consider that, for the first objective, we can wait to a certain degree to start ECMO, while for the second objective we have to be more proactive regarding ECMO. This is the challenge in 2015 while awaiting future significant technological improvements or new scientific proof of the efficacy of ECMO regarding ARDS outcome.

When considering this clinical vignette, this patient is a potential good candidate for ECMO, presenting single organ failure (the lung) with a short delay since intubation [3, 4]. At this point and regarding PEEP and plateau pressure level, we can assume that there is potential for oxygenation improvement by adjusting ventilator parameters. As this ARDS is severe, we should first paralyze this patient. After a bolus dose of a neuromuscular blocker, we have to institute continuous infusion of this drug. Immediately after, we must reassess ventilator parameters. We can increase PEEP and observe the concomitant rise in plateau pressure (if using a volume-controlled mode). The plateau pressure limit is highly dependent on the patient. If she is obese, plateau pressure of 32 cmH₂O would be within acceptable limits; otherwise, 30 cmH₂O is acceptable. However, as the cause of ARDS is community-acquired pneumonia (CAP), the distribution of lung lesions is probably heterogeneous. There is therefore a substantial risk of inefficacy of high PEEP levels related to huge differences in regional compliances. This is the reason why prone position has to be used early after adjusting PEEP level. Since the studies done by Mancebo [5], the meta-analysis of Gattinoni [6], and the PROSEVA study by Guérin [7], we know that

prone positioning can improve survival when applied early in the course of ARDS, when $\text{PaO}_2/\text{FiO}_2$ (P/F) ratio is lower than 150. It is therefore difficult to not consider prone positioning before implementing ECMO. Moreover, use of prone positioning has been shown to significantly reduce the need for ECMO in severe ARDS patients [7]. Just before proning the patient, it is essential to evaluate right ventricular function. The presence of right ventricular dysfunction could justify introduction of inhaled nitric oxide. However, improvement of oxygenation by itself can decrease right ventricular afterload by limiting pulmonary vasoconstriction. After turning the patient prone, PEEP level should be reevaluated [8] as the modification of repartition of lung densities can alter PEEP response. However, if after a few hours of proning, there is persistent severe hypoxemia (P/F <70–80 for centers without ECMO and needing to call a mobile unit; P/F <60–70 for ECMO centers), ECMO should be started promptly. To date, the benefit/risk ratio of ECMO treatment needs further evaluation. Therefore, attention should first be paid in this patient to elimination of any contraindication to heparin, any risk factor for intracerebral bleeding or immunosuppression. In this latter case, the prognosis of patients treated with ECMO has been shown to be poor [3, 4]. ECMO should ideally be provided with femoral–jugular cannulation at a flow of at least 60 % of the predicted cardiac output and a sweep gas flow to obtain a PaCO_2 compatible with $\text{pH} > 7.25$. No consensus exists on ventilator settings under ECMO. However, one study suggested better prognosis in patients with lower plateau pressure at day 1 after ECMO initiation [2]. Therefore, plateau pressure of 22–25 cmH_2O should be considered as acceptable, with driving pressure of 8–15 cmH_2O and resulting PEEP of 12–18 cmH_2O in order to rest the lung. As discussed above, as the cause of ARDS is CAP, the distribution of lung lesions is probably heterogeneous, and there is therefore substantial risk of inefficacy of high PEEP levels. However, the reduction of both tidal volume and driving pressure under ECMO may allow for higher PEEP levels than under conventional ventilation. Indeed, the risk of overdistension of anterior lung regions is reduced in this situation. Although the

prognostic impact of prone positioning under ECMO has not been evaluated, it has been shown to further improve oxygenation [9]. While prone positioning could be insufficient in this patient to prevent ECMO requirement, it should probably be continued after initiating ECMO if performed by trained teams [9]. Criteria for prone positioning initiation and weaning in ECMO patients remain to be evaluated in future studies.

In some patients, ECMO should be considered urgently for immediate life-threatening condition. In such cases, the benefit/risk ratio is very probably in favor of ECMO although the cost/benefit ratio may be questionable. When regarding the present clinical vignette, it is likely that, in this 51-year-old, previously healthy patient, a P/F ratio of 65 mmHg is safe for a period of time sufficient to discuss the indication for ECMO with an experienced team, ideally located in a reference center and equipped with a mobile team. Indeed, ECMO treatment may be associated with better prognosis when initiated and managed by highly trained personnel [10]. The cutoff for P/F ratio and the duration of hypoxemia before ECMO initiation are still a matter of debate and are currently being explored in ongoing randomized controlled trials (RCTs).

In conclusion, ECMO may be indicated in this patient, but not at this stage, since prone positioning has not been performed, having been shown to reduce the need for ECMO in severe ARDS patients [7]. However, in this patient without contraindication and with single organ failure, use of venovenous ECMO should be considered without delay if the P/F ratio decreases below 55–60 mmHg for at least 3 h, despite a protective ventilation strategy (including use of prone positioning). ECMO should be discussed if the P/F ratio is below 80 mmHg when $\text{FiO}_2 = 1$ for more than 6 h, despite a protective ventilation strategy (involving use of prone positioning) or in case of respiratory acidosis with $\text{pH} < 7.20$ for over 6 h despite a protective ventilation strategy [10].

Conflicts of interest A.R. and L.P. do not have any conflicts of interest to declare regarding this manuscript.

References

1. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM et al (2009) Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet* 374(9698):1351–1363
2. Pham T, Combes A, Roze H, Chevret S, Mercat A, Roch A et al (2013) Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. *Am J Respir Crit Care Med* 187(3):276–285
3. Roch A, Hraiech S, Masson E, Grisoli D, Forel JM, Boucekine M et al (2014) Outcome of acute respiratory distress syndrome patients treated with extracorporeal membrane oxygenation and brought to a referral center. *Intensive Care Med* 40(1):74–83

4. Schmidt M, Zogheib E, Roze H, Repesse X, Lebreton G, Luyt CE et al (2013) The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *Intensive Care Med* 39(10):1704–1713
5. Mancebo J, Fernandez R, Blanch L, Rialp G, Gordo F, Ferrer M et al (2006) A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. *Am J Respir Crit Care Med* 173(11):1233–1239
6. Gattinoni L, Carlesso E, Taccone P, Polli F, Guerin C, Mancebo J (2010) Prone positioning improves survival in severe ARDS: a pathophysiologic review and individual patient meta-analysis. *Minerva Anesthesiol* 76(6):448–454
7. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T et al (2013) Prone positioning in severe acute respiratory distress syndrome. *New Engl J Med* 368(23):2159–2168
8. Gainnier M, Michelet P, Thirion X, Arnal JM, Sainty JM, Papazian L (2003) Prone position and positive end-expiratory pressure in acute respiratory distress syndrome. *Crit Care Med* 31(12):2719–2726
9. Guervilly C, Hraiech S, Gariboldi V, Xeridat F, Dizier S, Toesca R et al (2014) Prone positioning during venovenous extracorporeal membrane oxygenation for severe acute respiratory distress syndrome in adults. *Minerva Anesthesiol* 80(3):307–313
10. Richard C, Argaud L, Blet A, Boulain T, Contentin L, Dechartres A et al (2014) Extracorporeal life support for patients with acute respiratory distress syndrome: report of a consensus conference. *Ann Intensive Care* 4:15